Breast Mucin Tumor-Specific Epitopes for Cancer Immunotherapy.
Annual rept. 1 Aug 94-31 Jul 95,
TEXAS TECH UNIV HEALTH SCIENCES CENTER AMARILLO
Pagination or Media Count:
The objectives of the research program are to study the structure-immunogenicity relationships of a hypoglycosylated human tumor-specific mucin common to breast and other adenocarcinomas, and the regulation of tumor-specific lymphoid cells that respond to the tumor-specific immunogen. Hypoglycosylation of breast mucin leads to exposure of a tumor-specific epitope TSE. The structural and immunogenic properties of the TSE are being examined using synthetic mucin peptides and recombinant mucin proteins that contain the TSE andor mutations in potential glycosylation sites surrounding the TSE. Protein structure and glycosylation patterns of these proteins are being examined by biochemical and physical spectroscopic techniques i.e., 1H-NMR, mass spectrometry, and surface analytical spectroscopies. Immunogenicity is being examined by the ability of by tumor- specific antibodies and tumor-specific cytotoxic T lymphocytes to reorganize the TSE. Understanding of the structure-immunogenicity relationships of tumor-specific immunogens, as well as the regulation of the lymphoid cells responding to the immunogen, is essential for maximizing the use of synthetic peptide immunogens and tumor-specific cells as a potential adoptive immunotherapy for patients with cancer, and the development of a potential vaccine against this disease.
- Anatomy and Physiology